OrthO-rhumatO | VOL 11 | N°5 | 2013
33
doute temps de passer des études strictement «diagnos-
tiques» et «transversales» à des études dites de «suivi» ou
«longitudinales». En effet, nos décisions thérapeutiques
sont le plus souvent basées sur l'évolution, les variations
des concentrations des biomarqueurs, plutôt que sur un
résultat biologique isolé. Comme souvent, ce point sou-
ligne encore la nécessaire collaboration entre néphrologie
et laboratoire de chimie clinique.
références
1. Kdigo clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of
Chronic Kidney disease-mineral and Bone disorder (CKd-mBd). Kidney int suppl 2009;s1-130.
2. mac Way F, lessard m, lafage-proust mh. pathophysiology of chronic kidney disease-mineral and
bone disorder. Joint Bone spine 2012;79:544-9.
3. Jadoul m, albert Jm, akiba t, et al. incidence and risk factors for hip or other bone fractures
among hemodialysis patients in the dialysis outcomes and practice patterns study. Kidney int
2006;70:1358-66.
4. Block ga, Klassen ps, lazarus Jm, et al. mineral metabolism, mortality, and morbidity in
maintenance hemodialysis. J am soc nephrol 2004;15:2208-18.
5. stevens la, djurdjev o, Cardew s, Cameron eC, levin a. Calcium, phosphate, and parathyroid
hormone levels in combination and as a function of dialysis duration predict mortality: evidence
for the complexity of the association between mineral metabolism and outcomes. J am soc
nephrol 2004;15:770-9.
6. Bervoets ar, spasovski gB, Behets gJ, et al. useful biochemical markers for diagnosing renal
osteodystrophy in predialysis end-stage renal failure patients. am J Kidney dis 2003;41:997-1007.
7. Coen g, Ballanti p, Bonucci e, et al. Bone markers in the diagnosis of low turnover osteodystrophy
in haemodialysis patients. nephrol dial transplant 1998;13:2294-302.
8. monier-Faugere mC, geng Z, mawad h, et al. improved assessment of bone turnover by the pth-
(1-84)/large C-pth fragments ratio in esrd patients. Kidney int 2001;60:1460-8.
9. urena p, hruby m, Ferreira a, ang Ks, de Vernejoul mC. plasma total versus bone alkaline
phosphatase as markers of bone turnover in hemodialysis patients. J am soc nephrol 1996;7:506-
12.
10. Cavalier e, delanaye p, moranne o. Variability of new bone mineral metabolism markers in
patients treated with maintenance hemodialysis: implications for clinical decision making. am J
Kidney dis 2013;61:847-8.
11. ricos C, alvarez V, Cava F, et al. Current databases on biological variation: pros, cons and progress.
scand J Clin lab invest 1999;59:491-500.
12. malluche hh, mawad hW, monier-Faugere mC. renal osteodystrophy in the first decade of the
new millennium: analysis of 630 bone biopsies in black and white patients. J Bone miner res
2011;26:1368-76.
13. Kovesdy Cp, quarles ld. Fibroblast growth factor-23: what we know, what we don't know, and
what we need to know. nephrol dial transplant 2013;28(9):2228-36.
14. Kalantar-Zadeh K, Kuwae n, regidor dl, et al. survival predictability of time-varying indicators of
bone disease in maintenance hemodialysis patients. Kidney int 2006;70:771-80.
15. Coco m, rush h. increased incidence of hip fractures in dialysis patients with low serum
parathyroid hormone. am J Kidney dis 2000;36:1115-21.
16. nussbaum sr, Zahradnik rJ, lavigne Jr, et al. highly sensitive two-site immunoradiometric
assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem
1987;33:1364-7.
17. slatopolsky e, Finch J, Clay p, et al. a novel mechanism for skeletal resistance in uremia. Kidney int
2000;58:753-61.
18. souberbielle JC, Boutten a, Carlier mC, et al. inter-method variability in pth measurement:
implication for the care of CKd patients. Kidney int 2006;70:345-50.
19. gao p, scheibel s, d'amour p, et al. development of a novel immunoradiometric assay exclusively
for biologically active whole parathyroid hormone 1-84: implications for improvement of accurate
assessment of parathyroid function. J Bone miner res 2001;16:605-14.
20. Coen g, Bonucci e, Ballanti p, et al. pth 1-84 and pth "7-84" in the noninvasive diagnosis of renal
bone disease. am J Kidney dis 2002;40:348-54.
21. lehmann g, stein g, huller m, schemer r, ramakrishnan K, goodman Wg. specific
measurement of pth (1-84) in various forms of renal osteodystrophy (rod) as assessed by bone
histomorphometry. Kidney int 2005;68:1206-14.
22. salusky iB, goodman Wg, Kuizon Bd, et al. similar predictive value of bone turnover using first-
and second-generation immunometric pth assays in pediatric patients treated with peritoneal
dialysis. Kidney int 2003;63:1801-8.
23. Cosman F, morgan dC, nieves JW, et al. resistance to bone resorbing effects of pth in black
women. J Bone miner res 1997;12:958-66.
24. sawaya Bp, Butros r, naqvi s, et al. differences in bone turnover and intact pth levels between
african american and Caucasian patients with end-stage renal disease. Kidney int 2003;64:737-
42.
25. melamed ml, eustace Ja, plantinga lC, et al. third-generation parathyroid hormone assays
and all-cause mortality in incident dialysis patients: the ChoiCe study. nephrol dial transplant
2008;23:1650-8.
26. national Kidney Foundation. K/doqi clinical practice guidelines for bone metabolism and disease
in chronic kidney disease. am J Kidney dis 2003;42:s1-201.
27. Cavalier e, delanaye p, Vranken l, et al. interpretation of serum pth concentrations with different
kits in dialysis patients according to the Kdigo guidelines: importance of the reference (normal)
values. nephrol dial transplant 2012;27:1950-6.
28. guideline Working group. Japanese society for dialysis therapy. Clinical practice guideline for
the management of secondary hyperparathyroidism in chronic dialysis patients. ther apher dial
2008;12:514-25.
29. qunibi W, Kalantar-Zadeh K. target levels for serum phosphorus and parathyroid hormone. semin
dial 2011;24:29-33.
30. gardham C, stevens pe, delaney mp, leroux m, Coleman a, lamb eJ. Variability of parathyroid
hormone and other markers of bone mineral metabolism in patients receiving hemodialysis. Clin J
am soc nephrol 2010;5:1261-7.
31. harris h. the human alkaline phosphatases: what we know and what we don't know. Clin Chim
acta 1990;186:133-50.
32. Cavalier e, delanaye p, Collette J, Krzesinski Jm, Chapelle Jp. evaluation of different bone markers in
hemodialyzed patients. Clin Chim acta 2006;371:107-11.
33. Coen g, Ballanti p, Balducci a, et al. serum osteoprotegerin and renal osteodystrophy. nephrol dial
transplant 2002;17:233-8.
34. delanaye p, dubois Be, Jouret F, Krzesinski Jm, moranne o, Cavalier e. parathormone and bone-
specific alkaline phosphatase for the follow-up of bone turnover in hemodialysis patients: is it so
simple? Clin Chim acta 2013;417:35-8.
35. Fletcher s, Jones rg, rayner hC, et al. assessment of renal osteodystrophy in dialysis patients: use
of bone alkaline phosphatase, bone mineral density and parathyroid ultrasound in comparison
with bone histology. nephron 1997;75:412-9.
36. hutchison aJ, Whitehouse rW, Boulton hF, et al. Correlation of bone histology with parathyroid
hormone, vitamin d3, and radiology in end-stage renal disease. Kidney int 1993;44:1071-7.
37. Jarava C, armas Jr, salgueira m, palma a. Bone alkaline phosphatase isoenzyme in renal
osteodystrophy. nephrol dial transplant 1996;11(suppl 3):43-6.
38. Jean g, souberbielle JC, granjon s, et al. Bone biomarkers in haemodialysis patients: Bone alkaline
phosphatase or ss-Crosslaps? nephrol ther 2013;9(3):154-9.
39. Jean g, souberbielle JC, Zaoui e, et al. total and bone-specific alkaline phosphatases in
haemodialysis patients with chronic liver disease. Clin Biochem 2012;45:436-9.
40. moore C, yee J, malluche h, et al. relationship between bone histology and markers of bone
and mineral metabolism in african-american hemodialysis patients. Clin J am soc nephrol
2009;4:1484-93.
41. Couttenye mm, d'haese pC, Van hoof Vo, et al. low serum levels of alkaline phosphatase of
bone origin: a good marker of adynamic bone disease in haemodialysis patients. nephrol dial
transplant 1996;11:1065-72.
42. lehmann g, ott u, Kaemmerer d, schuetze J, Wolf g. Bone histomorphometry and biochemical
markers of bone turnover in patients with chronic kidney disease stages 3 - 5. Clin nephrol
2008;70:296-305.
43. iimori s, mori y, akita W, et al. diagnostic usefulness of bone mineral density and biochemical
markers of bone turnover in predicting fracture in CKd stage 5d patients--a single-center cohort
study. nephrol dial transplant 2012;27:345-51.
44. Beddhu s, ma X, Baird B, Cheung aK, greene t. serum alkaline phosphatase and mortality in
african americans with chronic kidney disease. Clin J am soc nephrol 2009;4:1805-10.
45. Blayney mJ, pisoni rl, Bragg-gresham Jl, et al. high alkaline phosphatase levels in hemodialysis
patients are associated with higher risk of hospitalization and death. Kidney int 2008;74:655-63.
46. Kovesdy Cp, ureche V, lu Jl, Kalantar-Zadeh K. outcome predictability of serum alkaline
phosphatase in men with pre-dialysis CKd. nephrol dial transplant 2010;25:3003-11.
47. regidor dl, Kovesdy Cp, mehrotra r, et al. serum alkaline phosphatase predicts mortality among
maintenance hemodialysis patients. J am soc nephrol 2008;19:2193-203.
48. drechsler C, Verduijn m, pilz s, et al. Bone alkaline phosphatase and mortality in dialysis patients.
Clin J am soc nephrol 2011;6:1752-9.
49. Kobayashi i, shidara K, okuno s, et al. higher serum bone alkaline phosphatase as a predictor of
mortality in male hemodialysis patients. life sci 2012;90:212-8.
50. Cavalier e, rozet e, Carlisi a, et al. analytical validation of serum bone alkaline phosphatase (Bap
ostase) on liaison. Clin Chem lab med 2010;48:67-72.
51. Cavalier e, delanaye p, Carlisi a, Krzesinski Jm, Chapelle Jp. stability of intact parathyroid hormone
in samples from hemodialysis patients. Kidney int 2007;72:370-2.
52. sardiwal s, gardham C, Coleman ae, stevens pe, delaney mp, lamb eJ. Bone-specific alkaline
phosphatase concentrations are less variable than those of parathyroid hormone in stable
hemodialysis patients. Kidney int 2012;82(1):100-5.
53. garrett g, sardiwal s, lamb eJ, goldsmith dJ. pth--a particularly tricky hormone: why measure it
at all in kidney patients? Clin J am soc nephrol 2013;8(2):299-312..
54. Vasikaran s, eastell r, Bruyere o, et al. markers of bone turnover for the prediction of fracture
risk and monitoring of osteoporosis treatment: a need for international reference standards.
osteoporos int 2011;22:391-420.
55. halleen Jm, alatalo sl, suominen h, Cheng s, Janckila aJ, Vaananen hK. tartrate-resistant acid
phosphatase 5b: a novel serum marker of bone resorption. J Bone miner res 2000;15:1337-45.
56. nakasato yr, Janckila aJ, halleen Jm, Vaananen hK, Walton sp, yam lt. Clinical significance of
immunoassays for type-5 tartrate-resistant acid phosphatase. Clin Chem 1999;45:2150-7.
57. shidara K, inaba m, okuno s, et al. serum levels of trap5b, a new bone resorption marker
unaffected by renal dysfunction, as a useful marker of cortical bone loss in hemodialysis patients.
Calcif tissue int 2008;82:278-87.
58. Chu p, Chao ty, lin yF, Janckila aJ, yam lt. Correlation between histomorphometric parameters
of bone resorption and serum type 5b tartrate-resistant acid phosphatase in uremic patients on
maintenance hemodialysis. am J Kidney dis 2003;41:1052-9.
59. Koivula mK, risteli l, risteli J. measurement of aminoterminal propeptide of type i procollagen
(pinp) in serum. Clin Biochem 2012;45:920-7.
60. melkko J, hellevik t, risteli l, risteli J, smedsrod B. Clearance of nh2-terminal propeptides of
types i and iii procollagen is a physiological function of the scavenger receptor in liver endothelial
cells. J exp med 1994;179:405-12.
61. ueda m, inaba m, okuno s, et al. Clinical usefulness of the serum n-terminal propeptide of type i
collagen as a marker of bone formation in hemodialysis patients. am J Kidney dis 2002;40:802-9.
62. Kleerekoper m. Biochemical markers of bone remodeling. am J med sci 1996;312:270-7.
63. garnero p, hausherr e, Chapuy mC, et al. markers of bone resorption predict hip fracture in elderly
women: the epidos prospective study. J Bone miner res 1996;11:1531-8.
64. qvist p, Christgau s, pedersen BJ, schlemmer a, Christiansen C. Circadian variation in the serum
concentration of C-terminal telopeptide of type i collagen (serum Ctx): effects of gender, age,
menopausal status, posture, daylight, serum cortisol, and fasting. Bone 2002;31:57-61.
65. okabe r, nakatsuka K, inaba m, et al. Clinical evaluation of the elecsys beta-Crosslaps serum
assay, a new assay for degradation products of type i collagen C-telopeptides. Clin Chem
2001;47:1410-4.
66. reichel h, roth hJ, schmidt-gayk h. evaluation of serum beta-carboxy-terminal cross-linking
telopeptide of type i collagen as marker of bone resorption in chronic hemodialysis patients.
nephron Clin pract 2004;98:c112-c118.
67. malyszko J, Wolczynski s, Zbroch e, Brzosko s, malyszko J, mysliwiec m. serum crosslaps
correlations with serum iCtp and urine dpd in hemodialyzed and peritoneally dialyzed patients.
nephron 2001;87:283-5.
68. negri al, quiroga ma, Bravo m, et al. serum crosslaps as bone resorption marker in peritoneal
dialysis. perit dial int 2002;22:628-30.
69. graf s, Bohne J, hertel a. evaluation of Beta-Crosslaps in haemodialysis patients/. nephrol dial
transplant 2013;18(suppl 4):407.